TABLE 1.
Demographics, Baseline HIV Status, and Clinical Findings Related to COVID-19 Among HIV Patients Coinfected With SARS-COV-2
| Demographics and Baseline HIV Status | Total (N = 35) | Nonsevere Group (N = 20) | Severe Group (N = 15) | P |
| Age, median (IQR), yrs | 52.0 (36.0–57.0) | 50.5 (33.3–57.0) | 55.0 (44.0–63.0) | 0.277 |
| Gender | ||||
| Female | 2 (5.7%) | 1 (5.0%) | 1 (6.7%) | 1.000 |
| Male | 33 (94.3%) | 19 (95.0%) | 14 (93.3%) | |
| History of comorbidities (n/%)* | ||||
| Pulmonary disease | 2 (7.1%) | 1 (6.7%) | 1 (7.7%) | 1.000 |
| Tuberculosis | 2 (7.1%) | 1 (6.7%) | 1 (7.7%) | 1.000 |
| Hypertension | 7 (25.0%) | 4 (26.7%) | 3 (23.1%) | 1.000 |
| Diabetes | 3 (10.7%) | 1 (6.7%) | 2 (15.4%) | 0.583 |
| HBV | 2 (6.7%) | 2 (11.8%) | 0 (0.0%) | 0.492 |
| HCV | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | / |
| Comorbidities per patient, n* | 1.0 (0.0–1.8) | 1.0 (0.0–2.0) | 1.0 (0.0–1.5) | 0.749 |
| Alcohol consumption* | ||||
| Ever and current | 5 (17.9%) | 3 (20.0%) | 2 (15.4%) | 0.741 |
| Abtainer | 3 (10.7%) | 1 (6.7%) | 2 (15.4%) | |
| Never | 20 (71.4%) | 11 (73.3%) | 9 (69.2%) | |
| Smoking* | ||||
| Ever and current | 4 (14.3%) | 2 (13.3%) | 2 (15.4%) | 0.399 |
| Former | 5 (17.9%) | 4 (26.7%) | 1 (7.7%) | |
| Never | 19 (67.9%) | 9 (60.0%) | 10 (76.9%) | |
| Time elapse since HIV diagnosis, mo | 70.0 (42.0–91.0) | 62.0 (38.3–84.5) | 87.0 (47.0–106.0) | 0.199 |
| Interval between tests for HIV viral load, mo* | 12.0 (9.0–14.0) | 10.0 (9.0–13.0) | 14.0 (9.3–15.5) | 0.133 |
| Interval between tests for CD4+ cell count, mo* | 9.0 (6.0–12.0) | 9.0 (8.0–11.0) | 8.0 (6.0–13.8) | 0.833 |
| Severity of HIV infection | ||||
| HIV | 20 (57.1%) | 11 (55.0%) | 9 (60.0%) | 1.000 |
| AIDS | 15 (42.9%) | 9 (45.0%) | 6 (40.0%) | |
| Time elapse since ART, mo | 61.0 (34.0–80.0) | 49.0 (23.8–69.3) | 70.5 (42.3–87.0) | 0.111 |
| Current ART-regimen (n/%) | ||||
| AZT/ABC+3 TC+EFV/NVP | 16 (45.7%) | 8 (40.0%) | 8 (53.3%) | 0.381 |
| TDF+3 TC/FTC+EFV/NVP/RPV | 16 (45.7%) | 11 (55.0%) | 5 (33.3%) | |
| TDF+3 TC+DTG/LPV/r | 3 (8.6%) | 1 (5.0%) | 2 (13.3%) | |
| ART discontinuation (n/%)* | ||||
| Yes | 4 (14.3%) | 2 (13.3%) | 2 (15.4%) | 1.000 |
| No | 24 (85.7%) | 13 (86.7%) | 11 (84.6%) | |
| Clinical findings related to COVID-19 | ||||
| Time at onset (n/%) | ||||
| January, 2020 | 25 (71.4%) | 12 (60.0%) | 13 (86.7%) | 0.242 |
| February, 2020 | 8 (22.9%) | 6 (30.0%) | 2 (13.3%) | |
| March, 2020 | 1 (2.9%) | 1 (5.0%) | 0 (0.0%) | |
| April, 2020 | 1 (2.9%) | 1 (5.0%) | 0 (0.0%) | |
| Symptoms at onset (n/%) | ||||
| Fever | 25 (71.4%) | 13 (65.0%) | 12 (80.0%) | 0.458 |
| Dry cough | 13 (37.1%) | 8 (40.0%) | 5 (33.3%) | 0.737 |
| Shortness of breath | 8 (22.9%) | 2 (10.0%) | 6 (40.0%) | 0.051 |
| Gastrointestinal symptoms | 4 (11.4%) | 2 (10.0%) | 2 (13.3%) | 1.000 |
| None | 3 (8.6%) | 3 (15.0%) | 0 (0.0%) | 0.244 |
| Time from onset to medical visit, d | 6.0 (1.0–8.0) | 4.0 (0.3–8.0) | 6.0 (1.0–10.0) | 0.638 |
| Ever hospitalized for COVID-19 (n/%) | ||||
| Yes | 29 (82.9%) | 15 (75.0%) | 14 (93.3%) | 0.207 |
| No | 6 (17.1%) | 5 (25.0%) | 1 (6.7%) | |
| Days of hospital stay, d | 16.0 (11.5–32.5) | 13.0 (10.0–23.0) | 21.5 (13.8–36.3) | 0.101 |
| SARS-CoV-2 testing (n/%) | ||||
| PCR positive test | 24 (68.6%) | 13 (65.0%) | 11 (73.3%) | 0.721 |
| positive IgM test* | 1 (3.6%) | 0 (0.0%) | 1 (7.7%) | 0.464 |
| positive IgG test* | 22 (78.6%) | 11 (73.3%) | 11 (84.6%) | 0.655 |
| Outcome (n/%) | ||||
| Survived | 33 (94.3%) | 20 (100.0%) | 13 (86.7%) | 0.176 |
| Died | 2 (5.7%) | 0 (0.0%) | 2 (13.3%) | |
| With family members having COVID-19 (n/%)† | ||||
| Yes | 9 (27.3%) | 6 (30.0%) | 3 (23.1%) | 0.367 |
| No | 23 (69.7%) | 14 (70.0%) | 9 (69.2%) | |
| Unknown | 1 (3.0%) | 0 (0.0%) | 1 (7.7%) | |
| With colleagues having COVID-19 (n/%)† | ||||
| Yes | 4 (12.1%) | 3 (15.0%) | 1 (7.7%) | 0.275 |
| No | 25 (75.8%) | 16 (80.0%) | 9 (69.2%) | |
| Unknown | 4 (12.1%) | 1 (5.0%) | 3 (23.1%) |
Nonsevere group included patients with asymptomatic COVID-19, virally confirmed and clinically diagnosed COVID-19 with mild and moderate COVID-19.
Severe group included patients with virally confirmed and clinically diagnosed COVID-19 with severe and critical COVID-19.
A total of 28 coinfected patients included as 5 of the 33 survived COVID-19 patients refused to participate in our follow-up survey.
A total of 33 coinfected patients included as 2 of the 35 COVID-19 patients died at tele-survey.
ABC, abacavir; AZT, Zidovudine; COVID-19, coronavirus disease 2019; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; HBV, Hepatitis B virus; HCV, Hepatitis C virus; LPV/r, Lopinavir/Ritonavir; NVP, nevirapine; RPV, rilpivirine; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; 3 TC, lamivudine; TDF, tenofovir disoproxifumarate.